FACTBOX-Top biotech takeout targets of 2010 -Morningstar

NEW YORK March 9 (Reuters) - Here are the biotechnology companies most likely to be bought in 2010, according to analysts at Morningstar.

In assessing odds of a takeover, Morningstar said it weighed drug portfolio strength, fits with potential partners, profit-boosting power and financial health.

In pursuing acquisitions, product-hungry pharmaceutical companies appear increasingly undeterred by partnerships biotech companies have with rival drugmakers. [ID:nN09215904]

Many on Morningstar's list, including Vertex, Auxilium and Human Genome, have partnerships on their most promising drugs.

Here are the takeout targets with market value:

1) Vertex, $8.3 billion

2) Auxilium Pharma, $1.5 billion

3) Human Genome Sciences, $5.8 billion

4) InterMune, $1.3 billion

5) Celgene, $28.3 billion

6) Exelixis, $730 million

7) Genzyme, $15.2 billion

8) Crucell, $1.7 billion

9) Elan, $4.2 billion

10) BioMarin, $2.3 billion (Editing by Robert MacMillan)